Companies in Dermatology
There are 1,797 companies in Dermatology which include Revance Therapeutics, LEO Pharma, Incyte, Evommune, Verrica Pharmaceuticals. 623 companies in Dermatology are funded, with 350 having secured Series A funding. Till date, the sector has seen the creation of 1 Unicorn. United States has the most number of companies in Dermatology (569), followed by United Kingdom
(135), and then South Korea (113).
2026 has seen the creation of 9 Dermatology companies. On average, the last 10 years have seen 43 new companies launched every year. Most number of Dermatology startups have been founded by alumni from Massachusetts Institute of Technology, Harvard University and Stanford University.
Here is a List of top companies in Dermatology
Developer of neurotoxin aesthetic and therapeutic products for skin treatments. It focused on developing innovative products in the aesthetic medicine and personal wellness categories. It has developed a platform technology that enables the delivery of large macromolecules and other potent molecules across the skin. Its aesthetics pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines. It has the same products as therapies for Hyperhidrosis and Cervical Dystonia.
Key facts about Revance Therapeutics
- Founded Year: 2002
- Location: Newark (United States)
- Stage: Acquired
- Total Funding till date: $155M
- Investors: EW Healthcare Partners, Delphi Ventures and 17 Others
- Latest Funding Round: Series E, Oct 22, 2013, $*****
- Tracxn Score: 72/100 What is this?
- Competitors Rank: 1 of 262 Competitors
2. LEO Pharma
Developer of drugs for treating dermatology diseases. It offers variety of medicines such as topical creams and ointments, oral tablets, and injectable biologics for the treatment of psoriasis, eczema, and rare diseases. The pipeline products include Tralokinumab for atopic dermatitis and Delgocitinib a topical pan-JAK inhibitor for chronic hand eczema.
Key facts about LEO Pharma
- Founded Year: 1908
- Location: Copenhagen (Denmark)
- Stage: Late Stage
- Total Funding till date: $560M
- Investors: Nordic Capital
- Latest Funding Round: PE, Mar 31, 2022, $*****
- Tracxn Score: 71/100 What is this?
- Competitors Rank: 4 of 3,234 Competitors
3. Incyte
Developer of small molecules for the treatment of different cancer and skin diseases. The company provides Jakafi to treat polycythemia vera (PV) and myelofibrosis (MF). Its product pipeline includes Pemazyre for Cholangiocarcinoma3 Monjuv for lymphoma, Iclusig for chronic myeloid leukemia, ruxolitinib for chronic GVHD, and others.
Key facts about Incyte
- Founded Year: 1991
- Location: Wilmington (United States)
- Stage: Public
- Investors: BB Biotech, Tekla Capital Management and 5 Others
- Latest Funding Round: Post IPO, Nov 14, 2013, $*****
- Tracxn Score: 67/100 What is this?
- Competitors Rank: 35 of 4,259 Competitors
4. Evommune
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Key facts about Evommune
- Founded Year: 2020
- Location: Sacramento (United States)
- Stage: Public
- Total Funding till date: $276M
- Investors: Pivotal bioVenture Partners, RA Capital Management and 18 Others
- Latest Funding Round: Post IPO, Feb 12, 2026, $*****
- Tracxn Score: 67/100 What is this?
- Competitors Rank: 34 of 3,572 Competitors
Verrica is a developer of therapeutic solutions for skin diseases such as molluscum contagiosum, and others. It has developed a lead product, VP-100 is a topical film forming formulation, indicated for molluscum contagiosum and Verruca Vulgaris (common warts and plantar warts). VP-100 has completed phase II trials and the company is initiating pivotal phase III trials for Molluscum contagiosum. The company is also developing treatments for additional common dermal indications including Actinic Keratosis and Seborrheic Keratosis.
Key facts about Verrica Pharmaceuticals
- Founded Year: 2013
- Location: West Chester (United States)
- Stage: Public
- Total Funding till date: $27.4M
- Investors: Perceptive Advisors, avenuealtd.com and 4 Others
- Latest Funding Round: Post IPO, Nov 25, 2025, $*****
- Tracxn Score: 67/100 What is this?
- Competitors Rank: 34 of 3,234 Competitors
